These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 8246705)

  • 21. Mathematical models in decision analysis.
    Tom E; Schulman KA
    Infect Control Hosp Epidemiol; 1997 Jan; 18(1):65-73. PubMed ID: 9013249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian analysis of correlated evolution of discrete characters by reversible-jump Markov chain Monte Carlo.
    Pagel M; Meade A
    Am Nat; 2006 Jun; 167(6):808-25. PubMed ID: 16685633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes.
    Zhang Y; Wu H; Denton BT; Wilson JR; Lobo JM
    Health Care Manag Sci; 2019 Mar; 22(1):34-52. PubMed ID: 29080053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Graphical representation of life paths to better convey results of decision models to patients.
    Rubrichi S; Rognoni C; Sacchi L; Parimbelli E; Napolitano C; Mazzanti A; Quaglini S
    Med Decis Making; 2015 Apr; 35(3):398-402. PubMed ID: 25589524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy.
    Abler D; Kanellopoulos V; Davies J; Dosanjh M; Jena R; Kirkby N; Peach K
    J Radiat Res; 2013 Jul; 54 Suppl 1(Suppl 1):i49-55. PubMed ID: 23824126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding Events to a Markov Model Using DICE Simulation.
    Caro JJ; Möller J
    Med Decis Making; 2018 Feb; 38(2):235-245. PubMed ID: 28675959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian averaging over Decision Tree models for trauma severity scoring.
    Schetinin V; Jakaite L; Krzanowski W
    Artif Intell Med; 2018 Jan; 84():139-145. PubMed ID: 29275896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating risk attitude into Markov-process decision models: importance for individual decision making.
    Cher DJ; Miyamoto J; Lenert LA
    Med Decis Making; 1997; 17(3):340-50. PubMed ID: 9219195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A decision-analytic model for early stage breast cancer: lumpectomy vs mastectomy.
    Büyükdamgaci-Alogan G; Elele T; Hayran M; Erman M; Kiliçkap S
    Neoplasma; 2008; 55(3):222-8. PubMed ID: 18348655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bayesian method for construction of Markov models to describe dynamics on various time-scales.
    Rains EK; Andersen HC
    J Chem Phys; 2010 Oct; 133(14):144113. PubMed ID: 20949993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidelines for prevention of thromboembolic events in valvular heart disease. Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology.
    Gohlke-Bärwolf C; Acar J; Burckhardt D; Oakley C; Butchart E; Krayenbühl P; Hall R; Bodnar E; Krzeminska-Pakula M; Delahaye JP
    J Heart Valve Dis; 1993 Jul; 2(4):398-410. PubMed ID: 8269142
    [No Abstract]   [Full Text] [Related]  

  • 33. Markov Influence Diagrams.
    Díez FJ; Yebra M; Bermejo I; Palacios-Alonso MA; Calleja MA; Luque M; Pérez-Martín J
    Med Decis Making; 2017 Feb; 37(2):183-195. PubMed ID: 28076183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Markov Cohort State-Transition Model: A Multinomial Distribution Representation.
    Iskandar R; Berns C
    Med Decis Making; 2023 Jan; 43(1):139-142. PubMed ID: 35838344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical methods that distinguish between attributes of assessment: prolongation of life versus quality of life.
    Loewy JW; Kapadia AS; Hsi B; Davis BR
    Med Decis Making; 1992; 12(2):83-92. PubMed ID: 1573984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 1994 Mar; 71(3):286-91. PubMed ID: 8029791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
    Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.
    Hunink MG; Bult JR; de Vries J; Weinstein MC
    Med Decis Making; 1998; 18(3):337-46. PubMed ID: 9679999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thromboembolic events in prosthetic valve recipients: what is the safe level of anticoagulation?
    Acar J
    J Heart Valve Dis; 1993 Jul; 2(4):395-7. PubMed ID: 8269141
    [No Abstract]   [Full Text] [Related]  

  • 40. Utility evaluations for Markov states of lung cancer for PET-based disease management.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):186-90. PubMed ID: 10967627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.